REG - CVS Group plc - Directorate Change

CVSAnnouncement

22/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230622:nRSV4804Da&default-theme=true

RNS Number : 4804D  CVS Group plc  22 June 2023

 For Immediate Release  22 June 2023

 

CVS Group plc

("CVS", the "Company" or the "Group")

Appointments of non-executive director and Deputy CEO

CVS, the quoted provider of integrated veterinary services, is pleased to
announce the appointment of Joanne Shaw as Non-executive Director with effect
from 1 July 2023.

 

Joanne Mary Shaw (59), has significant healthcare experience from her current
roles as Trustee and Audit Committee Chair at Cancer Research UK, Chair at the
Royal College of Paediatrics and Child Health, and Deputy Chair at Vitality
UK.  She has held a number of previous non-executive roles over the past 17
years including as non-executive director and Chair of the Audit and Risk
Committee at NHS England and the National Audit Office, Chair of NHS Direct,
Non-executive Director at Kensington and Chelsea Primary Care Trust and Chair
of the British Equestrian Association.  Joanne, who qualified as a chartered
accountant, was a former management consultant at Boston Consulting Group and
has previous executive roles at the Medicines Partnership, the Audit
Commission and Coopers & Lybrand.

 

In her role of Non-executive Director, Joanne will become a member of the
Audit, Remuneration and Nominations committees of the Board.

 

The Board is also pleased to announce the appointment of Ben Jacklin, Chief
Operating Officer, to a newly created role of Deputy CEO, also with effect
from 1 July 2023. Ben will retain responsibility for leading the Group's
operations in the UK and internationally.

 

Chairman Richard Connell commented:

 

"On behalf of the Board I am delighted to welcome Joanne Shaw as a
Non-executive Director.  Her extensive healthcare experience will support the
Board and the wider Group in delivering its purpose to provide the best
possible care to animals.  The Board looks forward to her input and to
working together to deliver further success for the Group.

 

I am also delighted to congratulate Ben Jacklin on his promotion to Deputy CEO
which is a reflection of Ben's significant contribution to the Group over the
past few years."

 

 

Contacts:

 

CVS Group
plc
via Camarco

Richard Fairman, CEO

Ben Jacklin, COO

Robin Alfonso, CFO

 

Peel Hunt LLP (Nominated Adviser & Broker)
 
                +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

Berenberg (Joint
Broker)
+44 (0)20 3207 7800

Toby Flaux / Ben Wright / James Thompson / Milo Bonser

 

Camarco (Financial PR)
 
 

Geoffrey
Pelham-Lane
+44 (0)7733 124 226

Ginny
Pulbrook
+44 (0)7961 315 138

Letaba
Rimell
+44 (0)7789 151 644

 

 

 

Additional Disclosures under the AIM Rules for Companies:

 

In relation to the appointment of Joanne Shaw, aged 59:

 

Current directorships/partnerships
                  Past directorships/partnerships

                Royal College of Paediatrics & Child
Health
NHS England

                Cancer Research
UK
Nuffield Health

                Cancer Research UK Trading
Ltd
Discovery Holdings Europe Ltd

                Imperial Cancer Research
Fund

                Vitality Corporate Services Ltd

                Vitality Health
Ltd

                Vanguard Metropolitan
Ltd

 

At the date of this announcement Joanne Shaw does not hold any ordinary shares
in the Company.

 

Save for the above, there are no further disclosures to be made in accordance
with Rule 17 and 2 paragraph (g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUAVAROWUNUAR